United States-based Halodine LLC has collaborated with Emery Pharma, a boutique contract research and development company, it was reported on Thursday.
The collaboration is aimed at advancing the development of Halodine's proprietary antiseptic platform for COVID-19.
The partnership will see Emery Pharma's use its experience in antimicrobial and antiviral screening and drug development, while Halodine is to use its expertise in topical antiviral drug development.
Emery Pharma says that it will leverage its microbiology, virology, and bioanalytical experience to aid in developing this novel product, as well as other drugs to help treat COVID-19.
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
Champions Oncology expands bioanalytical services with new technology and leadership
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
Poolbeg Pharma trial to feature in major CRS research programme
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Proteome Sciences wins third US biopharma contract for new clinical assay
Lundbeck reports results from long-term follow-up of epilepsy patients treated with bexicaserin
CARsgen Therapeutics presents CT0596 study data at 2005 ASH Annual Meeting
AsymBio starts commercial production at Shanghai Fengxian Manufacturing Base
Innovent Biologics and Takeda sign global strategic partnership